EMEA-001864-PIP01-15-M04

Key facts

Invented name
Takhzyro
Active substance
Lanadelumab (DX-2930)
Therapeutic area
Other
Decision number
P/0265/2019
PIP number
EMEA-001864-PIP01-15-M04
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of hereditary angioedema attacks
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Shire Pharmaceuticals Ireland Limited

Tel. +39 02 65535076
E-mail: medinfoEMEA@shire.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating